Back to School: How biopharma can reboot drug development. Access exclusive analysis here

NM283: Final Phase I data

In a dose-escalation, placebo-controlled, double-blind, U.S. Phase I

Read the full 84 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE